Miyuki Nishimura

Biochemistry, Genetics and Molecular Biology · Life Sciences

20h-index5.7kcitations78works0.22yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Angiogenesis and VEGF in Cancer(20), Developmental Biology and Gene Regulation(19), Chemokine receptors and signaling(16), Microtubule and mitosis dynamics(15), T-cell and B-cell Immunology(9)

Publications77 total

Supplementary Figure S2 from Inhibition of Notch4 Using Novel Neutralizing Antibodies Reduces Tumor Growth in Murine Cancer Models by Targeting the Tumor Endothelium
2025Open Access
Supplementary Figure S1 from Inhibition of Notch4 Using Novel Neutralizing Antibodies Reduces Tumor Growth in Murine Cancer Models by Targeting the Tumor Endothelium
2025Open Access
Supplementary Figure S3 from Inhibition of Notch4 Using Novel Neutralizing Antibodies Reduces Tumor Growth in Murine Cancer Models by Targeting the Tumor Endothelium
2025Open Access
Supplementary Table 1 from Inhibition of Notch4 Using Novel Neutralizing Antibodies Reduces Tumor Growth in Murine Cancer Models by Targeting the Tumor Endothelium
2025Open Access
Supplementary Figure S4 from Inhibition of Notch4 Using Novel Neutralizing Antibodies Reduces Tumor Growth in Murine Cancer Models by Targeting the Tumor Endothelium
2025Open Access
Correction: Inhibition of Notch4 Using Novel Neutralizing Antibodies Reduces Tumor Growth in Murine Cancer Models by Targeting the Tumor Endothelium
Cancer Research Communications·2025Open Access
Supplementary Figure S4 from Inhibition of Notch4 Using Novel Neutralizing Antibodies Reduces Tumor Growth in Murine Cancer Models by Targeting the Tumor Endothelium
2025Open Access
Supplementary Figure S1 from Inhibition of Notch4 Using Novel Neutralizing Antibodies Reduces Tumor Growth in Murine Cancer Models by Targeting the Tumor Endothelium
2025Open Access
Supplementary Figure S2 from Inhibition of Notch4 Using Novel Neutralizing Antibodies Reduces Tumor Growth in Murine Cancer Models by Targeting the Tumor Endothelium
2025Open Access
Supplementary Figure S3 from Inhibition of Notch4 Using Novel Neutralizing Antibodies Reduces Tumor Growth in Murine Cancer Models by Targeting the Tumor Endothelium
2025Open Access
Supplementary Table 1 from Inhibition of Notch4 Using Novel Neutralizing Antibodies Reduces Tumor Growth in Murine Cancer Models by Targeting the Tumor Endothelium
2025Open Access
Supplementary Figure S1 from Inhibition of Notch4 Using Novel Neutralizing Antibodies Reduces Tumor Growth in Murine Cancer Models by Targeting the Tumor Endothelium
2024Open Access
Supplementary Figure S2 from Inhibition of Notch4 Using Novel Neutralizing Antibodies Reduces Tumor Growth in Murine Cancer Models by Targeting the Tumor Endothelium
2024Open Access
Supplementary Table 1 from Inhibition of Notch4 Using Novel Neutralizing Antibodies Reduces Tumor Growth in Murine Cancer Models by Targeting the Tumor Endothelium
2024Open Access
Supplementary Table 1 from Inhibition of Notch4 Using Novel Neutralizing Antibodies Reduces Tumor Growth in Murine Cancer Models by Targeting the Tumor Endothelium
2024Open Access
Supplementary Figure S1 from Inhibition of Notch4 Using Novel Neutralizing Antibodies Reduces Tumor Growth in Murine Cancer Models by Targeting the Tumor Endothelium
2024Open Access
Supplementary Figure S4 from Inhibition of Notch4 Using Novel Neutralizing Antibodies Reduces Tumor Growth in Murine Cancer Models by Targeting the Tumor Endothelium
2024Open Access
Supplementary Figure S3 from Inhibition of Notch4 Using Novel Neutralizing Antibodies Reduces Tumor Growth in Murine Cancer Models by Targeting the Tumor Endothelium
2024Open Access
Supplementary Figure S2 from Inhibition of Notch4 Using Novel Neutralizing Antibodies Reduces Tumor Growth in Murine Cancer Models by Targeting the Tumor Endothelium
2024Open Access
Supplementary Figure S4 from Inhibition of Notch4 Using Novel Neutralizing Antibodies Reduces Tumor Growth in Murine Cancer Models by Targeting the Tumor Endothelium
2024Open Access
page 1 of 4Next →

Frequent Co-authors

Toshio Imai(42), Yoshimasa Sakamoto(23), Kana Hoshino‐Negishi(23), Jason W.‐L. Eng(22), Yusuke Adachi(22), Bhairavi Swaminathan(22), L.A. Naiche(22), Rahul Vadakath(22), Youya Nakazawa(22), Sho Tachino(22), Ken Ito(22), Yukinori Minoshima(22), Hideaki Ogasawara(22), Tomomi Kawakatsu(22), Masahiko Katayama(22), Masashi Shimizu(22), Kazuhiro Tahara(22), Toshitaka Sato(22), Katsuhisa Suzuki(22), Kishan Agarwala(22)